Dfb Oncology

DFB Oncology is a clinical-stage biotechnology company and a subsidiary of DFB Pharmaceuticals focused on developing novel oncology therapeutics. The company primarily operates through its joint venture, NanOlogy, which utilizes a proprietary Large Surface Area Microparticle (LSAM) technology platform to deliver high concentrations of chemotherapy agents directly to tumor sites. Their lead programs involve submicron particle formulations of paclitaxel and docetaxel, aimed at treating solid tumors such as pancreatic, prostate, and ovarian cancers. By minimizing systemic exposure and maximizing local drug concentration, DFB Oncology seeks to improve efficacy and reduce the toxicity associated with traditional chemotherapy.